OralDosed ingredientTherapeutic flag Cosmetic cross-reference

Sulindac

CAS 38194-50-2

Sulindac (CAS 38194-50-2) is a Phase 4 pharmaceutical compound with 11 bioactivity targets and 170 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

170

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Sulindac

CAS Number

38194-50-2

UNII

184SNS8VUH

InChIKey

MLKXDPUZXIRXEP-MFOYZWKCSA-N

ChEMBL ID

CHEMBL15770

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

black box warningdosed ingredientoraltherapeutic flag

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)

Approved or marketed human pharmaceutical use is represented in the source phase field.

ChEMBL CHEMBL15770 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 19 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	AC50	20878.557765957445 nM	91	-
-	Potency	22342.178260869565 nM	35	-
-	IC50	44082.87481481482 nM	26	-
-	Kd	34663.333333333336 nM	3	-
-	EC50	11515 nM	2	-
-	Ki	77900 nM	1	-
Prostaglandin G/H synthase 2 Enzyme	IC50	4.25	-	Homo sapiens
Prostaglandin G/H synthase 1 Enzyme	IC50	5.92	-	Homo sapiens
Glycine receptor subunit alpha-1 Ion channel	EC50	6.42	-	Homo sapiens
Aldose reductase Enzyme	IC50	6.43	-	Homo sapiens
Peroxisome proliferator-activated receptor gamma Nuclear hormone receptor	EC50	4.64	-	Homo sapiens
Retinoic acid receptor RXR-alpha Nuclear hormone receptor	IC50	4.08	-	Homo sapiens
72 kDa type IV collagenase Enzyme	-	-	-	Homo sapiens
Lactoylglutathione lyase Enzyme	Ki	4.11	-	Homo sapiens
Aldose reductase Enzyme	IC50	6.362	-	Rattus norvegicus
Prostaglandin G/H synthase 1 Enzyme	IC50	4.8	-	Ovis aries
Prostaglandin E synthase Enzyme	IC50	4.1	-	Homo sapiens
Complement C5 Secreted	Kd	6.24	-	Homo sapiens
Bile salt export pump Transporter	IC50	4.06	-	Rattus norvegicus

SOURCE DrugCentral 10 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Drug hypersensitivity	114	124.347	10013700
Hangover	10	34.959	10019133
Nodal osteoarthritis	7	27.664	10029469
Inflammatory pain	7	27.11	10065390
Crystal nephropathy	7	26.288	10071503
Gastric haemorrhage	12	23.203	10017788
Dry gangrene	6	22.732	10049927
Musculoskeletal chest pain	13	18.763	10050819
Musculoskeletal discomfort	12	18.287	10053156
Intestinal diaphragm disease	4	18.144	10064749

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE IUPHAR/BPS 3 interactions

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

Target	Action	Affinity	PubMed
COX-1 PTGS1	Inhibition	5.920000076293945 pIC50	20541701
COX-2 PTGS2	Inhibition	5.46999979019165 pIC50	20541701
Retinoid X receptor-α RXRA	Antagonist	4.099999904632568 pIC50	20541701

SOURCE PharmGKB 4 phenotype rows

Pharmacogenomics

Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.

FMO3 (PA166) rs2266782

Genotype AA is associated with increased exposure to sulindac in healthy individuals as compared to genotype GG.

Evidence: -; PMID 28331852

FMO3 (PA166) rs2266780

Genotype GG is associated with increased exposure to sulindac in healthy individuals as compared to genotype AA.

Evidence: -; PMID 28331852

FMO3 rs2266782

Evidence: 3; PMID 1

FMO3 rs2266780

Evidence: 3; PMID 1

SOURCE NLM RxNorm 2 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
SULINDAC	10237	SU	MTHSPL
sulindac	10237	IN	RXNORM

SOURCE SIDER 80 side-effect rows

Side Effects

SIDER side-effect terms mapped to the drug or same-CAS compound identity.

Side Effect	Drug Name	MedDRA Type	Concept ID
Acute psychosis	sulindac	LLT	C0281774
Acute psychosis	sulindac	PT	C0281774
Adenitis	sulindac	LLT	C0001416
Ageusia	sulindac	LLT	C2364111
Ageusia	sulindac	PT	C2364111
Agranulocytosis	sulindac	LLT	C0001824
Agranulocytosis	sulindac	PT	C0001824
Allergic cutaneous angiitis	sulindac	LLT	C0151436
Alopecia	sulindac	LLT	C0002170
Alopecia	sulindac	PT	C0002170
Anaemia	sulindac	LLT	C0002871
Anaemia	sulindac	PT	C0002871
Anaphylactic shock	sulindac	LLT	C0002792
Anaphylactic shock	sulindac	PT	C0002792
Angioedema	sulindac	LLT	C0002994
Angioedema	sulindac	PT	C0002994
Anorexia	sulindac	LLT	C0003123
Aplastic anaemia	sulindac	LLT	C0002874
Aplastic anaemia	sulindac	PT	C0002874
Arrhythmia	sulindac	LLT	C0003811
Arrhythmia	sulindac	PT	C0003811
Arthralgia	sulindac	LLT	C0003862
Arthralgia	sulindac	PT	C0003862
Arthritis	sulindac	LLT	C0003864
Arthritis	sulindac	PT	C0003864
Asthenia	sulindac	LLT	C0004093
Asthenia	sulindac	PT	C0004093
Asthenia	sulindac	PT	C0004093
Biliary sludge	sulindac	LLT	C0282074
Body temperature increased	sulindac	LLT	C0015967
Body temperature increased	sulindac	PT	C0015967
Bone marrow depression	sulindac	LLT	C0151773
Bronchospasm	sulindac	LLT	C0006266
Bronchospasm	sulindac	PT	C0006266
Calculus of kidney	sulindac	LLT	C0022650
Cardiac failure congestive	sulindac	LLT	C0018802
Cardiac failure congestive	sulindac	PT	C0018802
Cellulitis gangrenous	sulindac	PT	C0854456
Chest pain	sulindac	LLT	C0008031
Chest pain	sulindac	PT	C0008031
Chills	sulindac	LLT	C0085593
Chills	sulindac	PT	C0085593
Cholecystitis	sulindac	LLT	C0008325
Cholecystitis	sulindac	PT	C0008325
Cholelithiasis	sulindac	PT	C0008350
Cholestasis	sulindac	LLT	C0008370
Cholestasis	sulindac	PT	C0008370
Chromaturia	sulindac	PT	C0541832
Colitis	sulindac	LLT	C0009319
Colitis	sulindac	PT	C0009319
Coma	sulindac	LLT	C0009421
Coma	sulindac	PT	C0009421
Conjunctivitis	sulindac	LLT	C0009763
Conjunctivitis	sulindac	PT	C0009763
Constipation	sulindac	LLT	C0009806
Constipation	sulindac	PT	C0009806
Convulsion	sulindac	LLT	C0036572
Convulsion	sulindac	PT	C0036572
Crystalluria	sulindac	LLT	C0151579
Crystalluria	sulindac	PT	C0151579
Decreased appetite	sulindac	PT	C0232462
Depressed level of consciousness	sulindac	PT	C0549249
Depression	sulindac	LLT	C0011570
Depression	sulindac	PT	C0011570
Dermatitis	sulindac	PT	C0011603
Dermatitis exfoliative	sulindac	LLT	C0011606
Dermatitis exfoliative	sulindac	PT	C0011606
Diarrhoea	sulindac	LLT	C0011991
Diarrhoea	sulindac	PT	C0011991
Discomfort	sulindac	PT	C0234215
Disseminated intravascular coagulation	sulindac	LLT	C0012739
Disseminated intravascular coagulation	sulindac	PT	C0012739
Dizziness	sulindac	LLT	C0012833
Dizziness	sulindac	PT	C0012833
Dizziness	sulindac	PT	C0012833
Drug reaction with eosinophilia and systemic symptoms	sulindac	PT	C1142139
Dysgeusia	sulindac	PT	C0013378
Dyspepsia	sulindac	LLT	C0013395
Dyspepsia	sulindac	PT	C0013395
Dyspnoea	sulindac	LLT	C0013404

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Sulindac used for in pharmaceutical contexts?

Sulindac (CAS 38194-50-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Sulindac?

Sulindac has 170 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Drug hypersensitivity, Hangover, Nodal osteoarthritis, Inflammatory pain, Crystal nephropathy. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Sulindac also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Sulindac with EU status "permitted".

What clinical phase is Sulindac in?

Sulindac is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Sulindac?

Sulindac has 19 bioactivity rows in this page query. Rendered target entries include Prostaglandin G/H synthase 2, Prostaglandin G/H synthase 1, Glycine receptor subunit alpha-1, Aldose reductase, Peroxisome proliferator-activated receptor gamma.